시장보고서
상품코드
1457149

조산(PL) 시장 - 경쟁 상황

Premature Labor (PL) -Competitive Landscape

발행일: | 리서치사: GlobalData | 페이지 정보: 영문 68 Pages | 배송안내 : 즉시배송

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

조산(PL)은 2023년 16개 국가에서 500만 명 이상이 조산할 것으로 예측됩니다. 현재 시판 중인 PL 치료제는 광범위하게 제네릭화되어 있으며, 대부분의 PL 치료제는 β2 아드레날린 수용체 길항제이며, PL 치료제 파이프라인에 있는 13개 약물 중 단 1개만이 임상 3상 단계에 있습니다.

지난 10년간 시작된 PL 관련 임상시험의 25% 이상이 북미 전역에서 진행되었습니다. 지난 10년간 PL 개발사가 참여한 거래 중 북미와 유럽에서 가장 많은 인수가 이루어졌습니다.

이 보고서는 전 세계 조산(PL) 시장을 조사하여 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

  • 질병 개요
  • 역학 개요
  • 치료 개요

제4장 출시 약제 평가

  • 주요 출시 약제
  • 작용기서별 개요
  • 투여 경로별 개요
  • 출시 약제 프로파일과 판매량 예측

제5장 약가 설정과 상환 평가

  • 연간 치료비
  • 약가 설정과 상환 기간

제6장 파이프라인 약제 평가

  • 제III상 파이프라인 약제
  • 개발 단계별 개요
  • 분자 유형별 개요
  • 작용기서별 개요
  • 투여 경로별 개요
  • 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
  • 치료 분야 및 적응증 고유의 PTSR 및 LoA

제7장 임상시험 평가

  • 역사적 개요
  • 상별 개요
  • 상황별 개요
  • 진행중 및 계획중인 시험의 상별 개요
  • 가상 컴포넌트를 사용한 임상시험
  • 지역적 개요
  • 지역별 단일국 및 다국적 시험
  • 상위 20개 스폰서와 상별 내역
  • 상위 20개 스폰서 상황별 내역
  • 엔드포인트 상황별 개요
  • 인종 및 민족별 개요
  • 등록 데이터
  • 임상시험 사이트 상위 20개국
  • 세계의 상위 20개 사이트
  • 실현 가능성 분석 - 지역적 개요
  • 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

  • 주요 시장 진출 기업

제10장 향후 시장 성장 촉진요인

제11장 부록

ksm 24.04.12

This reports provides a data-driven overview of the current and future competitive landscape in PL therapeutics.

  • More than 5,000,000 total prevalent cases of PL are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for PL.
  • Marketed drugs for PL are widely genericized and the majority of drugs indicated to treat PL are beta-2 adrenergic receptor antagonists.
  • Out of 13 drugs in the pipeline for PL, only one is in the Phase III stage of development.
  • More than 25% of the clinical trials initiated over the last 10 years for PL have been conducted in sites across North America.
  • In deals involving companies developing PL assets that occurred during past 10 years, acquisition was the most prevalent deal type in North America and Europe.

Scope

GlobalData's PL: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the PL market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PL market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Contents
  • 1.2 Report Scope
  • 1.3 List of Tables and Figures
  • 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

  • 3.1 Disease Overview
  • 3.2 Epidemiology Overview
  • 3.3 Treatment Overview

4 Marketed Drugs Assessment

  • 4.1 Leading Marketed Drugs
  • 4.2 Overview by Mechanism of Action
  • 4.3 Overview by Route of Administration
  • 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

  • 5.1 Annual Therapy Cost
  • 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

  • 6.1 Phase III Pipeline Drugs
  • 6.2 Overview by Development Stage
  • 6.3 Overview by Molecule Type
  • 6.4 Overview by Mechanism of Action
  • 6.5 Overview by Route of Administration
  • 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
  • 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

  • 7.1 Historical Overview
  • 7.2 Overview by Phase
  • 7.3 Overview by Status
  • 7.4 Overview by Phase for Ongoing and Planned Trials
  • 7.5 Trials with Virtual Components
  • 7.6 Geographic Overview
  • 7.7 Single-Country and Multinational Trials by Region
  • 7.8 Top 20 Sponsors with Breakdown by Phase
  • 7.9 Top 20 Sponsors with Breakdown by Status
  • 7.10 Overview by Endpoint Status
  • 7.11 Overview by Race and Ethnicity
  • 7.12 Enrollment Data
  • 7.13 Top 20 countries for Trial Sites
  • 7.14 Top 20 Sites Globally
  • 7.15 Feasibility Analysis - Geographic Overview
  • 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

  • 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
  • 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

  • 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

  • 11.1 Methodology
  • 11.2 Methodology - Sales Forecast
  • 11.3 Methodology - Pricing and Reimbursement
  • 11.4 Methodology - PTSR and LoA Analysis
  • 11.5 About the Authors
  • 11.6 Contact Us
  • 11.7 Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제